Compare RELL & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | NVCT |
|---|---|---|
| Founded | 1947 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.6M | 171.9M |
| IPO Year | N/A | 2022 |
| Metric | RELL | NVCT |
|---|---|---|
| Price | $10.97 | $7.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 52.9K | ★ 94.5K |
| Earning Date | 01-06-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $209,791,000.00 | N/A |
| Revenue This Year | $4.72 | N/A |
| Revenue Next Year | $14.93 | N/A |
| P/E Ratio | $903.34 | ★ N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $7.57 | $4.44 |
| 52 Week High | $15.51 | $11.52 |
| Indicator | RELL | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 73.30 |
| Support Level | $10.75 | $6.47 |
| Resistance Level | $11.47 | $6.84 |
| Average True Range (ATR) | 0.42 | 0.40 |
| MACD | 0.11 | 0.17 |
| Stochastic Oscillator | 75.00 | 92.00 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.